Viatris (VTRS) FCF Payout Ratio Growth (1y) (2022 - 2026)
Viatris (VTRS) FCF Payout Ratio Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 92.25 Bn | 90.38 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.58 Bn | 32.83 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn | 15.81% |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn | -130.26% |
| 5 | RedHill Biopharma | 23.06 Bn | 23.06 Bn | - | - |
| 6 | United Therapeutics | 22.81 Bn | 20.66 Bn | 648.10 Mn | - |
| 7 | Viatris | 20.68 Bn | 18.88 Bn | 1.16 Bn | 37.82% |
| 8 | Neurocrine Biosciences | 18.35 Bn | 17.03 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.70 Bn | 12.28 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.32 Bn | 10.17 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.82% |
| Dec 31, 2025 | -46.70% |
| Sep 30, 2025 | 11.26% |
| Jun 30, 2025 | 84.50% |
| Mar 31, 2025 | 14.99% |
| Dec 31, 2024 | 17.16% |
| Sep 30, 2024 | -1.84% |
| Jun 30, 2024 | 44.36% |
| Mar 31, 2024 | 62.35% |
| Dec 31, 2023 | -91.33% |
| Sep 30, 2023 | 2.35% |
| Jun 30, 2023 | 55.41% |
| Mar 31, 2023 | 15.27% |
| Dec 31, 2022 | 909.38% |
| Sep 30, 2022 | 37.92% |
| Jun 30, 2022 | -28.43% |